For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous
prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Not exact matches
Spearheaded by first author Christopher McNair, PhD, a graduate student in the laboratory of Dr. Knudsen, the study undertook an extensive analysis of tumor samples and
cell - free DNA samples
from patients with advanced, lethal - stage
prostate cancer.
But by sequencing the entire genomes of seven
prostate tumors and comparing them with genomes
from the
patients» normal
cells, the researchers discovered an unexpected phenomenon.
Furthermore, they found that D4A is more effective than abiraterone at killing aggressive
prostate cancer
cells, suggesting that some
patients may benefit
from direct treatment with D4A.
In the case of gene editing, Verma is creating induced pluripotent stem
cells (iPSCs)
from patients by taking, for example, skin
cells of
patients, coaxing them back into an early stem
cell state, and then providing conditions to make those
cells develop into more complex brain, lung,
prostate and breast tissues.
The team is currently working on genome sequencing of individual circulating tumour
cells from patients at the Vancouver
Prostate Centre.
A study funded by the US Public Health Service studied the effects of pomegranate juice on
prostate cancer
cells taken
from patients and determined that pomegranate extract was able to slow down the growth of cancer in these
cells.